March 13, 2020 / 12:07 PM / 22 days ago

BRIEF-Merck And Pfizer Provide Update On Phase III Javelin Head And Neck 100 Study

March 13 (Reuters) - Merck KGaA:

* MERCK AND PFIZER PROVIDE UPDATE ON PHASE III JAVELIN HEAD AND NECK 100 STUDY

* MERCK KGAA - ALLIANCE ACCEPTED RECOMMENDATION OF INDEPENDENT DATA MONITORING COMMITTEE (DMC) TO TERMINATE JAVELIN HEAD AND NECK 100 TRIAL

* MERCK KGAA - TO TERMINATE AS STUDY UNLIKELY TO SHOW STATISTICALLY SIGNIFICANT IMPROVEMENT IN PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL

* MERCK KGAA - DETAILED ANALYSIS OF PHASE III JAVELIN HEAD AND NECK 100 STUDY CONDUCTED AND STUDY FINDINGS TO BE SHARED WITH THE SCIENTIFIC COMMUNITY Source text - bit.ly/39SmV9e Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below